Compare Figs Inc (FIGS) vs Heron Therapeutics Inc (HRTX) Price & Performance

FIGS trades at $10.08, up 3.7% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $631.1M in 2025 (Zacks Investment Research, 2026-05-07), but net cash flow remains negative. Analyst consensus is Buy with a $19.50 target, though technical indicators show selling pressure.

Outlook hinges on global expansion and margin management amid cost pressures. Risks include competitive threats and volatile cash flows, but strong customer growth and premium positioning offer upside if execution improves.

HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.

The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.